Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Topical Epigallocatechin-3-gallate (EGCG) in Patients With Breast Cancer Receiving Adjuvant Radiotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02580279
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:20.791703+00:00
Published At
2019-04-05T00:00:00+00:00
Record Updated At
2019-04-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Breast Neoplasms", "Dermatitis", "Prevention \u0026 Control", "Epigallocatechin Gallate"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-04-05"
protocolSection.identificationModule.nctId
"NCT02580279"
protocolSection.identificationModule.officialTitle
"Phase II Study of Topical Epigallocatechin-3-gallate (EGCG) in Patients With Breast Cancer Receiving Adjuvant Radiotherapy"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Breast Neoplasms (protocolSection.conditionsModule.conditions)
  • Dermatitis (protocolSection.conditionsModule.conditions)
  • Prevention & Control (protocolSection.conditionsModule.conditions)
  • Epigallocatechin Gallate (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.